Multivariate quantitative analysis of glycan impact on IgG1 effector functions

Area of Science:

• Biochemistry
• Immunology
• Biotechnology

Background:

• Understanding the structure-function relationship of therapeutic proteins, especially glycosylation's impact on IgG effector functions, is critical for novel biologics and biosimilars.
• Regulatory agencies emphasize the importance of glycosylation patterns in therapeutic protein development.

Purpose of the Study:

• To introduce a systematic, multivariate approach for understanding and predicting the impact of Fc glycans on therapeutic protein effector functions.
• To provide quantitative models for predicting glycan effects on Fc gamma receptor (FcγR) binding and bioactivity.

Main Methods:

• Utilized a combination of Design of Experiments (DoE), multivariate data analysis, and in vitro glycoengineering.
• Applied various analytical assays, including binding and cell-based assays, to investigate individual glycan effects on IgG1.
• Adhered to Quality-by-Design (QbD) principles and regulatory guidelines.

Main Results:

• A 1% decrease in Fc fucosylation correlated with a >25% increase in antibody-dependent cell-mediated cytotoxicity (ADCC).
• Developed regression models that quantitatively explain and predict the influence of specific glycan features on FcγR binding and bioactivity.
• Demonstrated the challenge of studying individual glycan effects due to intercorrelated patterns and low variability in process samples.

Conclusions:

• The developed systematic approach offers a powerful tool for advancing therapeutic monoclonal antibody development by quantitatively assessing glycosylation impacts.
• This methodology aligns with regulatory expectations and Quality-by-Design principles, facilitating more predictable and robust bioprocess development.